BioXcel Therapeutics

💊 Neuropharmaceuticals· 📍 New Haven, CT, USA

Overview

BioXcel Therapeutics is developing BXCL501, a sublingual film formulation of dexmedetomidine for acute agitation in bipolar disorder and schizophrenia, leveraging AI-driven drug repurposing.

More in Neuropharmaceuticals

Neurogenix Therapeutics

Basel, Switzerland

Acadia Pharmaceuticals

San Diego, USA

Acer Therapeutics

Newton, MA, USA

Praxis Precision Medicine

Cambridge, MA, USA

Axsome Therapeutics

New York, USA

Athira Pharma

Bothell, WA, USA

Latest industry news

It's Finally Here: FacialDx, an AI-Powered Support Tool for Sideline Concussion Assessments

2026-06-23 · Product

MIT Researchers Demonstrate Real-Time Emotion Decoding via Non-Invasive EEG with 94% Accuracy

2026-06-13 · Research

Synchron Launches Stentrode Home Edition, Expanding BCI Access Beyond Clinical Settings

2026-06-11 · Product

Synchron Reaches 100-Patient Milestone as Stentrode BCI Moves Toward Pivotal Trial

2026-06-09 · Industry

Company details

Is this your company?

Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.

Claim & upgrade listing

Advertise

Reach neurotech professionals

Newsletter sponsorships, featured listings, and sponsored articles.

View packages →